ritlecitinib

FDA Drug Profile — Litfulo

ritlecitinib is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Litfulo. Available dosage form: capsule.

Drug details

Generic Name
ritlecitinib
Brand Names
Litfulo
Application Number
NDA215830
Sponsor
Pfizer Manufacturing Deutschland GmbH
NDC Codes
3
Dosage Forms
CAPSULE
Routes
ORAL
Active Ingredients
RITLECITINIB TOSYLATE

Indications and Usage

1 INDICATIONS AND USAGE LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. ( 1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants ( 1 ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.